EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effect of Treatment with Progestins and Antiplatelet Agents on IVF in Women with Adenomyosis and Recurrent Implantation Failure

Irina Pacu iD, Nikolaos Zygouropoulos iD, Giorgia Zampieri, Aida Petca iD, Mircea Octavian Poenaru iD, Cringu Antoniu Ionescu

Diagnostics · 26.12.2024 · 15 (1) · 30

DOI: 10.3390/diagnostics15010030 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diagnostics, online erschienen am 26.12.2024. Verfasst von Irina Pacu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics & Gynecology, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Medicine and Pharmacy Carol Davila.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This prospective study aims to identify the effect of the dienogest 2 mg/day and aspirin 150 mg/day combined treatment for two months before frozen ET on the assisted reproduction outcome in women with adenomyosis and recurrent implantation failure (RIF).

Methods

Patients were selected based on specific criteria and divided into two groups (with and without treatment). Preimplantation biochemical parameters and ultrasonographic features (endometrial thickness, uterine peristalsis, and junctional zone thickness) were compared with pregnancy rate in a non-natural cycle frozen embryo transfer technique. A comparison between the two study groups indicated an increased successful implantation rate and clinical pregnancy rate (25% vs. 7.4%).

Results

These results were attributed to the reduced uterine peristalsis and the reduction in thickness of the junctional zone following treatment. Available data were limited due to the nature of the study though maximal effort was exerted for the selected patients between groups to be as demographically similar and free from other potential pathology that may affect the results.

Conclusions

In conclusion, it appears that the above stated treatment improves outcomes in women with adenomyosis and RIF; the parameters used may provide an insight as to the reasons why this occurs, though an explanation of the molecular mechanisms is still elusive.

Schlagwörter

Stichwörter der Autor:innen

adenomyosisjunctional zonerecurrent implantation failureuterine peristaltic wave

Autor:innen und Institutionen

  • Department of Obstetrics & Gynecology, Faculty of Medicine, "Carol Davila" University of Medicine and Pharmacy, 020021 Bucharest, Romania.
  • "St. Pantelimon" Emergency Clinical Hospital, 021623 Bucharest, Romania.
  • "Elias" Emergency University Hospital, 011461 Bucharest, Romania.
  • "Bucur" Maternity, Saint Ioan Emergency Clinical Hospital, 012363 Bucharest, Romania.

ORCID-Profile: Irina Pacu, Nikolaos Zygouropoulos, Aida Petca, Mircea Octavian Poenaru

Förderung

  • University of Medicine and Pharmacy Carol Davila

Zitieren

APA

Pacu, I., Zygouropoulos, N., Zampieri, G., Petca, A., Poenaru, M. O., & Ionescu, C. A. (2024). Effect of Treatment with Progestins and Antiplatelet Agents on IVF in Women with Adenomyosis and Recurrent Implantation Failure. Diagnostics, 15(1), 30. https://doi.org/10.3390/diagnostics15010030

Vancouver

Pacu I, Zygouropoulos N, Zampieri G, Petca A, Poenaru MO, Ionescu CA. Effect of Treatment with Progestins and Antiplatelet Agents on IVF in Women with Adenomyosis and Recurrent Implantation Failure. Diagnostics. 2024;15(1):30. doi:10.3390/diagnostics15010030

BibTeX
@article{Pacu2024,
  author = {Pacu, Irina and Zygouropoulos, Nikolaos and Zampieri, Giorgia and Petca, Aida and Poenaru, Mircea Octavian and Ionescu, Cringu Antoniu},
  title = {Effect of Treatment with Progestins and Antiplatelet Agents on IVF in Women with Adenomyosis and Recurrent Implantation Failure},
  journal = {Diagnostics},
  year = {2024},
  volume = {15},
  number = {1},
  pages = {30},
  doi = {10.3390/diagnostics15010030}
}
Kostenlos starten →